Last edition
News about Market
ELMED Life Sciences Raises USD 2.7 Million to Scale Probiotic Manufacturing and Global Expansion
ELMED Life Sciences, a science-driven company specializing in probiotic and biological solutions, has raised USD 2.7 million (approximately INR 25 crore) in a Series A funding round led by AgriSURE Fund, managed by NABVENTURES.
Market | 26/03/2026 | By Darshana | 126
Against this backdrop, Integris MedTech has distinguished itself among Indian peers through its execution speed, disciplined integration approach, and ability to translate acquisitions into scalable market access rather than isolated capacity expansion. Its strategy aligns well with the broader industry shift toward platform-driven growth.
Market | 26/03/2026 | By Darshana
Endogenex Raises USD 50 Million to Advance Novel Diabetes Treatment
Series C extension led by Arboretum Ventures to fund pivotal clinical study and support regulatory pathway for ReCET System.
Market | 26/03/2026 | By News Bureau | 142
PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan
Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.
Market | 25/03/2026 | By News Bureau | 234
Bio-Thera Expands Partnership with Intas for BAT2506 Biosimilar in India
Bio-Thera has expanded its partnership with Intas Pharmaceuticals to commercialise BAT2506, a proposed golimumab biosimilar, in India.
Market | 24/03/2026 | By News Bureau | 128
Gilead Sciences to Acquire Ouro Medicines in USD 2 Billion Deal to Strengthen Immunology Pipeline
Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a deal valued at over USD 2 billion, marking a strategic move to expand its immunology and inflammation pipeline.
Market | 24/03/2026 | By Darshana
CVC and Apollo Partner to Accelerate Syntegon's Next Growth Phase
CVC has reaffirmed its confidence in Syntegon’s growth strategy as Apollo acquires a 37 percent minority stake to support expansion—particularly in the US—following strong performance that saw revenue reach a record €1.75 billion and operating profit quadruple, with further growth planned under CEO Torsten Türling.
Market | 23/03/2026 | By News Bureau | 112
The acquisition marks a significant strategic move for Abbott, enabling the company to expand into high-growth segments of cancer screening and diagnostics.
Market | 23/03/2026 | By Darshana | 174
Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity
Sun Pharmaceutical Industries has introduced semaglutide injections in India under the brands Noveltreat and Sematrinity, expanding access to advanced therapies for chronic weight management and type 2 diabetes. The launch strengthens treatment options with multiple dose strengths tailored to patient needs alongside diet and lifestyle interventions.
Market | 21/03/2026 | By News Bureau | 535
Eris Lifesciences Launches Weekly Semaglutide Shot at INR 220 in India
Eris Lifesciences has launched a weekly Semaglutide injection starting at INR 220 per dose and plans to introduce a pen-device version in April, priced between INR 4,000 and INR 4,500 per month to enhance patient convenience and adoption.
Market | 21/03/2026 | By News Bureau | 371
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy